Nordic Nanovector - Småprat 2 2020 - 2021 (NANOV) 1

[TekBot]

Nordic Nanovector Appoints Experienced Pharmaceutical Company Leader Peter L. Braun as Chief Executive Officer

Oslo, Norway, 17 March 2021

Nordic Nanovector ASA (OSE: NANOV) announces the appointment of Peter L. Braun
…

Vis børsmeldingen

as Chief Executive Officer (CEO). He will take up the position on 6 April 2021
and will be based in the company’s office in Zug, Switzerland.

Mr Braun is an experienced and entrepreneurial pharmaceutical leader, with
extensive commercialisation experience with innovative oncology products and
deep knowledge of pharmaceutical markets worldwide from a career spanning nearly
30 years at Hoffmann-La-Roche (“Roche”).

During his career at Roche, Mr Braun led the Lifecycle Management teams for the
successful targeted cancer therapies Herceptin® (trastuzumab) and Tarceva®
(erlotinib).

Mr Braun has also held various operational leadership positions including being
country general manager and multiple commercial roles in Europe, US and Latin
America. He has developed expertise across multiple strategic and operational
roles including development, manufacturing, business development and market
access for innovative therapeutic products in several geographies and other
therapeutic areas, including rare diseases and infectious diseases.

In addition to his experience at Roche, Mr Braun has also held roles at an
artificial intelligence (AI)-driven life sciences start-up and as strategy
consultant to emerging healthcare companies.

Jan H. Egberts, Chairman of Nordic Nanovector’s Board of Directors, said: “I am
delighted that Peter has agreed to join us at this important time for Nordic
Nanovector. Our aim was to leverage on our important recent progress by
recruiting a strong commercial CEO who can refine and drive the company’s plans
towards the regulatory filing and commercialisation of Betalutin®. We are
confident that, with Peter’s track record in and enthusiasm for the development
and commercialisation of innovative targeted oncology products, we can build on
the top-line data from the PARADIGME trial expected later in the year by clearly
defining our plans for Betalutin®’s commercialisation. These are key steps on
our path to becoming a leader in targeted radiopharmaceuticals.”

“I would like to take this opportunity to thank Lars Nieba for his leadership of
the company during the last 12 months as Interim CEO. His dedication and efforts
have contributed to the considerable progress Nordic Nanovector has made in this
time.”

Mr Braun added: “I am looking forward to this exciting new role as the CEO of
Nordic Nanovector. It is clear that targeted cancer therapeutics represent an
important treatment modality and well tolerated, targeted radiopharmaceuticals,
such as Betalutin®, can make a real difference to patients. I look forward to
working closely with the Board and the leadership team to bring this innovative
drug to NHL patients worldwide.”

When joining Nordic Nanovector, Mr Braun will be granted 350,000 PSUs
(performance share units) as part of the company’s annual grant of PSUs in the
first quarter of 2021.

For further information about the PSUs and the related warrants, see page 28 in
the company’s annual report for 2019.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Malene Brondberg, Chief Financial Officer at
Nordic Nanovector ASA, on 17 March 2021 at 2355 CET.

Kilde

[F-Tosca]

Flere enn meg som fant en tannlege? Gjør et nytt søk…

[Savepig]

@TekBot

Peter L. Braun

Er vel like vanlig som Ola H Nordmann hehe. Ikke det enkleste navnet å google.

Spennende!

[Montebello]

https://www.linkedin.com/mwlite/in/peterlbraun

[F-Tosca]

Så den, @Montebello . Men var på jakt etter et intervju eller noe sånt…

[BioMed]

Nordic Nanovector Appoints Experienced Pharmaceutical Company Leader Peter L. Braun as Chief Executive Officer

WED, MAR 17, 2021 23:55 CET

Oslo, Norway, 17 March 2021

Nordic Nanovector ASA (OSE: NANOV) announces the appointment of Peter L. Braun as Chief Executive Officer (CEO). He will take up the position on 6 April 2021 and will be based in the company’s office in Zug, Switzerland.

Mr Braun is an experienced and entrepreneurial pharmaceutical leader, with extensive commercialisation experience with innovative oncology products and deep knowledge of pharmaceutical markets worldwide from a career spanning nearly 30 years at Hoffmann-La-Roche (“Roche”).

During his career at Roche, Mr Braun led the Lifecycle Management teams for the successful targeted cancer therapies Herceptin® (trastuzumab) and Tarceva® (erlotinib).

Mr Braun has also held various operational leadership positions including being country general manager and multiple commercial roles in Europe, US and Latin America. He has developed expertise across multiple strategic and operational roles including development, manufacturing, business development and market access for innovative therapeutic products in several geographies and other therapeutic areas, including rare diseases and infectious diseases.

In addition to his experience at Roche, Mr Braun has also held roles at an artificial intelligence (AI)-driven life sciences start-up and as strategy consultant to emerging healthcare companies.

Jan H. Egberts, Chairman of Nordic Nanovector’s Board of Directors, said: “I am delighted that Peter has agreed to join us at this important time for Nordic Nanovector. Our aim was to leverage on our important recent progress by recruiting a strong commercial CEO who can refine and drive the company’s plans towards the regulatory filing and commercialisation of Betalutin®. We are confident that, with Peter’s track record in and enthusiasm for the development and commercialisation of innovative targeted oncology products, we can build on the top-line data from the PARADIGME trial expected later in the year by clearly defining our plans for Betalutin®’s commercialisation. These are key steps on our path to becoming a leader in targeted radiopharmaceuticals.”

“I would like to take this opportunity to thank Lars Nieba for his leadership of the company during the last 12 months as Interim CEO. His dedication and efforts have contributed to the considerable progress Nordic Nanovector has made in this time.”

Mr Braun added: “I am looking forward to this exciting new role as the CEO of Nordic Nanovector. It is clear that targeted cancer therapeutics represent an important treatment modality and well tolerated, targeted radiopharmaceuticals, such as Betalutin®, can make a real difference to patients. I look forward to working closely with the Board and the leadership team to bring this innovative drug to NHL patients worldwide.”

When joining Nordic Nanovector, Mr Braun will be granted 350,000 PSUs (performance share units) as part of the company’s annual grant of PSUs in the first quarter of 2021.

For further information about the PSUs and the related warrants, see page 28 in the company’s annual report for 2019.

[Mr_Bane]

Til Nieba. Får håpe han blir værende.

[Pk2k]

@F-Tosca

Så den, @Montebello . Men var på jakt etter et intervju eller noe sånt…

Fant et klipp hvertfall

Peter Braun, Head of Global Public Affaris, about Sustainability at Roche

[BioMed]

@Pk2k

Fant et klipp hvertfall

Improving access to cancer treatment

[Pk2k]

Lars forblir CTO vil jeg tro

[Savepig]

Endelig en CEO som snakker dønn perfekt engelsk.

[sjerkyll]

Roche has entered the lobby…?

[Teejay]

Tenkte det samme
Tiden for «lost in translation» og spekulative tolkninger er kanskje herved over

[hgsd300]

Lars Nieba comes from Bayer AG, where he served as VP and strategic product lead. He joined Bayer in 2016, following 13 years at F. Hoffmann-La Roche.

Braun, from a career spanning nearly 30 years at Hoffmann-La-Roche (“Roche”).

[anon57124368]

Spennende, da blir det utbytter om fem år og ikke leting etter nye investeringscaser for penger av salg. Litt kjedeligere, men klager ikke

[Fornybar]

Fornybar Trading (FornybarTI)

Det er ikke småpenger han har forvaltet!

(måtte fikse en unøyaktighet)

[Netromo]

Ser bra ut! Håper Nieba blir værende i selskapet.

[InVivo]

@anon57124368

Spennende, da blir det utbytter om fem

Hæ??

[anon57124368]

At vi tar det til markedet selv, istedet for å bli solgt. Ser på denne ansettelsen som svært langsiktig

[InVivo]

Til informasjon så er det ikke opp til ledelsen å vurdere ett bud på selskapet